Home
>
US Stocks
>
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
CRNX

Crinetics Pharmaceuticals Inc

$19.8711.37%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
20.3
Today Low/High
19.87 / 20.32
52 Week Low/High
$11.61 / $23.58
Market Cap
$847.24M

Company Details

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing CRN04777, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company's drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company
Organisation
Crinetics Pharmaceuticals Inc
Headquaters
San Diego, California, United States
Employees
93
Industry
Health Technology
CEO
R. Scott Struthers

Discover more

Frequently Asked Questions

What is Crinetics Pharmaceuticals Inc share price today

Can Indians buy Crinetics Pharmaceuticals Inc shares?

How can I buy Crinetics Pharmaceuticals Inc shares from India?

Can Fractional shares of Crinetics Pharmaceuticals Inc be purchased?

What are the documents required to start investing in Crinetics Pharmaceuticals Inc stocks?

We are a SEBI registered investement advisor